Gene
FOXC2
forkhead box C2
Explore in graph →CI-GENE-00002133HGNC:3801 ENSG00000176692 NCBI 2303 CIViC Approved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32110058
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FOXC2 Overexpression1 | ||||||||
| Oxaliplatin | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | D | Supports Resistance | 4 | submitted | EID8084Continuous exposure to oxaliplatin was used to produce an oxaliplatin resistant HCT116 cell line (HCT116/OXA), that showed significantly higher IC50 (145.5 ± 3.52 μM vs. 7.53 ± 0.63 μM) than the paren… (full text at CIViC) PMID 32110058 · Chen et al., 2020 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (0)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
Data not yet available
No cohort frequency recorded for this gene.
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.